Yeah I’m not sure of the distinction between the different classifications - it does sound like there is overlap. Fast track allows more interaction, think priority review is for a yes/no for approval more quickly is my quick reading of it - someone else can add more nuance if they’d like to.
the point I was making is I don’t think Imugene will get a voucher - it’s for tropical, rare paediatric, and medical countermeasures only, other things for cancer I guess, like accelerated approval etc?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $82.39M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 36.0¢ | $342.2K | 938.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 488 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 12566 | 2 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |